mirADAM · Blood microRNAs ADAM10-target: novel diagnostic and prognostic biomarkers for Alzheimer's disease by electrochemical sensors

Blood microRNAs ADAM10-target: novel diagnostic and prognostic biomarkers for Alzheimer's disease by electrochemical sensors

This project addresses the growing global challenge of Alzheimer’s Disease (AD), a neurodegenerative disorder that significantly impacts the elderly population. AD is closely linked to Type 2 Diabetes (T2D), with evidence suggesting that T2D increases the risk of developing AD due to shared mechanisms such as insulin resistance and amyloid-beta (Aβ) accumulation. ADAM10, a protein involved in the non-amyloidogenic cleavage of amyloid precursor protein (APP), has emerged as a promising biomarker for AD. However, its regulation, particularly by microRNAs (miRNAs), remains poorly understood. Additionally, current diagnostic methods for AD are invasive, expensive, and inaccessible to many, highlighting the need for innovative, cost-effective, and less invasive solutions. Objectives: 1. Identify and validate circulating miRNAs targeting ADAM10 that are deregulated in AD, T2D, and AD+T2D patients, and assess their diagnostic and prognostic value. 2. Develop a novel diagnostic device using validated miRNA panels for ADAM10 detection, leveraging electrochemical sensors for a low-cost, sensitive, and non-invasive approach. 3. Advance understanding of ADAM10 regulation and its role in the pathophysiology of AD and T2D, contributing to the development of therapeutic strategies. Project Pathway to Impact: 1. Scientific Impact: The project will enhance knowledge of miRNA regulation of ADAM10, providing insights into the molecular mechanisms underlying AD and T2D. It will also establish miRNA panels as potential biomarkers for early diagnosis and prognosis of AD. 2. Technological Innovation: The development of a patented diagnostic device based on miRNA panels will offer a low-cost, sensitive, and accessible alternative to current diagnostic methods, reducing patient discomfort and healthcare costs. 3. Societal Impact: Early detection of AD through the diagnostic device could enable timely interventions, potentially delaying disease progression and improving quality of life for patients. The device’s affordability and ease of use will make it accessible to underserved populations, addressing health inequities. 4. Economic Impact: By reducing the costs associated with AD diagnosis and treatment, the project could alleviate financial pressures on healthcare systems, particularly in low-income settings. Pathway: • Work Package 1 (WP1): Screening and identification of miRNAs targeting ADAM10 in healthy controls, AD, T2D, and AD+T2D groups. • Work Package 2 (WP2): Validation of identified miRNAs and their application in a diagnostic device using electrochemical sensors. • Work Package 3 (WP3): Regular meetings and collaboration among international research teams to ensure effective project management. • Work Package 4 (WP4): Training and skill development for the researcher, including patent writing and innovation courses. • Work Package 5 (WP5): Dissemination and exploitation of results through scientific publications, conferences, outreach activities, and patent applications. By integrating molecular biology, biotechnology, pharmacology, and gerontology, this interdisciplinary project aims to deliver impactful scientific, societal, and economic outcomes, fostering innovation in AD diagnosis and treatment.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз